Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

Microbes and Infection

Volumn 17, Issue 2, 2015, Pages 142-148

  Ying, Tianlei ^a   Li, Haoyang ^a   Lu, Lu ^a   Dimitrov, Dimiter S ^b   Jiang, Shibo ^a,c  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

Coronavirus; MAbs; MERS CoV; Receptor binding domain (RBD)

Indexed keywords

ANTIVIRUS AGENT; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EPIDEMIC; HUMAN; INFECTION PREVENTION; LIFE THREAT; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION; VIRUS NEUTRALIZATION; COMMUNICABLE DISEASE CONTROL; CORONAVIRUS INFECTIONS; IMMUNOLOGY; MIDDLE EAST; SERODIAGNOSIS; VIROLOGY;

CORONAVIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; COMMUNICABLE DISEASE CONTROL; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NEUTRALIZATION TESTS;

EID: 84921604371     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.11.008     Document Type: Article

References (67)

1. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
2. Lu L., Liu Q., Du L., Jiang S. Middle east respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microb Infect 2013, 15:625-629.
3. Hotez P.J., Bottazzi M.E., Tseng C.T., Zhan B., Lustigman S., Du L., et al. Calling for rapid development of a safe and effective MERS vaccine. Microb Infect 2014, 16:529-531.
4. Dimitrov D.S. Therapeutic proteins. Methods Mol Biol 2012, 899:1-26.
5. Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol 2006, 6:343-357.
6. Schrama D., Reisfeld R.A., Becker J.C. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006, 5:147-159.
7. Casadevall A., Dadachova E., Pirofski L.A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004, 2:695-703.
8. Zhang M.Y., Choudhry V., Xiao X., Dimitrov D.S. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Curr Opin Mol Ther 2005, 7:151-156.
9. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004, 101:2536-2541.
10. ter Meulen J., Bakker A.B., van den Brink E.N., Weverling G.J., Martina B.E., Haagmans B.L., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004, 363:2139-2141.
11. Traggiai E., Becker S., Subbarao K., Kolesnikova L., Uematsu Y., Gismondo M.R., et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004, 10:871-875.
12. Yang Z.Y., Werner H.C., Kong W.P., Leung K., Traggiai E., Lanzavecchia A., et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A 2005, 102:797-801.
13. ter Meulen J., van den Brink E.N., Poon L.L., Marissen W.E., Leung C.S., Cox F., et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006, 3:e237.
14. Zhu Z., Chakraborti S., He Y., Roberts A., Sheahan T., Xiao X., et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 2007, 104:12123-12128.
15. Tyrrell D.A., Bynoe M.L. Cultivation of a novel type of common-cold virus in organ cultures. Br Med J 1965, 1:1467-1470.
16. Hamre D., Procknow J.J. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 1966, 121:190-193.
17. McIntosh K., Dees J.H., Becker W.B., Kapikian A.Z., Chanock R.M. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A 1967, 57:933-940.
18. Bradburne A.F., Bynoe M.L., Tyrrell D.A. Effects of a "new" human respiratory virus in volunteers. Br Med J 1967, 3:767-769.
19. Bradburne A.F., Somerset B.A. Coronative antibody tires in sera of healthy adults and experimentally infected volunteers. J Hyg (Lond) 1972, 70:235-244.
20. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348:1953-1966.
21. Hafner S. SARS attacks!. Microb Infect 2013, 15:85-87.
22. van der Hoek L., Pyrc K., Jebbink M.F., Vermeulen-Oost W., Berkhout R.J., Wolthers K.C., et al. Identification of a new human coronavirus. Nat Med 2004, 10:368-373.
23. Woo P.C., Lau S.K., Chu C.M., Chan K.H., Tsoi H.W., Huang Y., et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005, 79:884-895.
24. Pyrc K., Berkhout B., van der Hoek L. The novel human coronaviruses NL63 and HKU1. J Virol 2007, 81:3051-3057.
25. Assiri A., Al-Tawfiq J.A., Al-Rabeeah A.A., Al-Rabiah F.A., Al-Hajjar S., Al-Barrak A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013, 13:752-761.
26. van Boheemen S., de Graaf M., Lauber C., Bestebroer T.M., Raj V.S., Zaki A.M., et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012, 3.
27. Lau S.K., Li K.S., Tsang A.K., Lam C.S., Ahmed S., Chen H., et al. Genetic characterization of betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J Virol 2013, 87:8638-8650.
28. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Muller M.A., Dijkman R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495:251-254.
29. Annan A., Baldwin H.J., Corman V.M., Klose S.M., Owusu M., Nkrumah E.E., et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 2013, 19:456-459.
30. Anthony S.J., Ojeda-Flores R., Rico-Chavez O., Navarrete-Macias I., Zambrana-Torrelio C.M., Rostal M.K., et al. Coronaviruses in bats from Mexico. J Gen Virol 2013, 94:1028-1038.
31. Hemida M.G., Perera R.A., Wang P., Alhammadi M.A., Siu L.Y., Li M., et al. MIDDLE EAST respiratory syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 2013, 18:20659.
32. Reusken C.B., Ababneh M., Raj V.S., Meyer B., Eljarah A., Abutarbush S., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill 2013, 18:20662.
33. Barlan A., Zhao J., Sarkar M.K., Li K., McCray P.B., Perlman S., et al. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J Virol 2014, 88:4953-4961.
34. Reusken C.B., Haagmans B.L., Muller M.A., Gutierrez C., Godeke G.J., Meyer B., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013, 13:859-866.
35. Yang Y., Du L., Liu C., Wang L., Ma C., Tang J., et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A 2014, 111:12516-12521.
36. de Wilde A.H., Jochmans D., Posthuma C.C., Zevenhoven-Dobbe J.C., van Nieuwkoop S., Bestebroer T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014, 58:4875-4884.
37. Dyall J., Coleman C.M., Hart B.J., Venkataraman T., Holbrook M.R., Kindrachuk J., et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014, 58:4885-4893.
38. Falzarano D., de Wit E., Rasmussen A.L., Feldmann F., Okumura A., Scott D.P., et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013, 19:1313-1317.
39. Lu L., Liu Q., Zhu Y., Chan K.H., Qin L., Li Y., et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014, 5:3067.
40. Shadman K.A., Wald E.R. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 2011, 11:1455-1467.
41. Zhu Z., Dimitrov A.S., Bossart K.N., Crameri G., Bishop K.A., Choudhry V., et al. Potent neutralization of hendra and nipah viruses by human monoclonal antibodies. J Virol 2006, 80:891-899.
42. Bossart K.N., Zhu Z., Middleton D., Klippel J., Crameri G., Bingham J., et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 2009, 5:e1000642.
43. Bossart K.N., Geisbert T.W., Feldmann H., Zhu Z., Feldmann F., Geisbert J.B., et al. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 2011, 3:105ra3.
44. Lingwood D., McTamney P.M., Yassine H.M., Whittle J.R., Guo X., Boyington J.C., et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 2012, 489:566-570.
45. Mascola J.R., Haynes B.F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 2013, 254:225-244.
46. Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., et al. Reversion of advanced ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
47. Hofmann H., Hattermann K., Marzi A., Gramberg T., Geier M., Krumbiegel M., et al. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 2004, 78:6134-6142.
48. Hsueh P.R., Huang L.M., Chen P.J., Kao C.L., Yang P.C. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 2004, 10:1062-1066.
49. Nie Y., Wang G., Shi X., Zhang H., Qiu Y., He Z., et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 2004, 190:1119-1126.
50. Subbarao K., McAuliffe J., Vogel L., Fahle G., Fischer S., Tatti K., et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004, 78:3572-3577.
51. Du L., Kou Z., Ma C., Tao X., Wang L., Zhao G., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013, 8:e81587.
52. Mou H., Raj V.S., van Kuppeveld F.J., Rottier P.J., Haagmans B.L., Bosch B.J. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013, 87:9379-9383.
53. Du L., Zhao G., Yang Y., Qiu H., Wang L., Kou Z., et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014, 88:7045-7053.
54. Ying T., Du L., Ju T.W., Prabakaran P., Lau C.C., Lu L., et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014, 88:7796-7805.
55. Jiang L., Wang N., Zuo T., Shi X., Poon K.M., Wu Y., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014, 6:234ra59.
56. Tang X.C., Agnihothram S.S., Jiao Y., Stanhope J., Graham R.L., Peterson E.C., et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A 2014, 111:E2018-E2026.
57. de Wit E., Prescott J., Baseler L., Bushmaker T., Thomas T., Lackemeyer M.G., et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in syrian hamsters. PLoS One 2013, 8:e69127.
58. Coleman C.M., Matthews K.L., Goicochea L., Frieman M.B. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 2014, 95:408-412.
59. Falzarano D., de Wit E., Feldmann F., Rasmussen A.L., Okumura A., Peng X., et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog 2014, 10:e1004250.
60. Zhao J., Li K., Wohlford-Lenane C., Agnihothram S.S., Fett C., Zhao J., et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 2014, 111:4970-4975.
61. Bregenholt S., Jensen A., Lantto J., Hyldig S., Haurum J.S. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr Pharm Des 2006, 12:2007-2015.
62. Nelson A.L., Reichert J.M. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009, 27:331-337.
63. Ying T., Chen W., Gong R., Feng Y., Dimitrov D.S. Soluble monomeric IgG1 Fc. J Biol Chem 2012, 287:19399-19408.
64. Ying T., Chen W., Feng Y., Wang Y., Gong R., Dimitrov D.S. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem 2013, 288:25154-25164.
65. Ying T., Ju T.W., Wang Y., Prabakaran P., Dimitrov D.S. Interactions of IgG1 CH2 and CH3 domains with FcRn. Front Immunol 2014, 5:146.
66. Ying T., Gong R., Ju T.W., Prabakaran P., Dimitrov D.S. Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta 2014, 1844:1977-1982.
67. Ying T., Feng Y., Wang Y., Chen W., Dimitrov D.S. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. mAbs 2014, 6:1201-1210.